TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01030692

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo groups will receive the same dosage throughout the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivastigmine 3 mg
Description: The 3 mg rivastigmine group will receive 3 mg rivastigmine only in the evening of Day 1, 3 mg in the morning and 0 mg in the evening of Days 2-9, and 3 mg in the morning of Day 10.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Huperzine A 0.4 mg
Description: The 0.4 mg HupA group will receive 0.2 mg HupA only in the evening of Day 1, 0.2 mg in the morning and evening of Days 2-9, and 0.2 mg in the morning of day 10.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivastigmine 6 mg
Description: The 6 mg rivastigmine group will receive 3 mg rivastigmine only in the evening of Day 1, 3 mg in the morning and 0 mg in the evening of Days 2-5, 3 mg in the morning and evening of Days 6-9, and 3 mg in the morning of Day 10.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Huperzine A 0.8 mg
Description: The 0.8 mg HupA group will receive 0.2 mg HupA only in the evening of Day 1, 0.2 mg in the morning and evening of Days 2-5, 0.4 mg in the morning and evening of Days 6-9, and 0.4 mg in the morning of Day 10.
Study: NCT02409511

Intervention type: OTHER
Intervention: non intervention

Intervention type: OTHER
Intervention: non intervention

Intervention type: OTHER
Intervention: non intervention

Intervention type: OTHER
Intervention: non intervention

Intervention type: OTHER
Intervention: non intervention
Study: NCT00437216

Intervention type: DRUG
Intervention: Clobetasol Propionate, 0.05%
Description: Apply twice daily for 2 or 4 weeks as monotherapy

Intervention type: DRUG
Intervention: Clobetasol propionate, 0.05% Spray
Description: Apply twice daily for 2 or 4 weeks as add-on therapy
Study: NCT04120155

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Dissection of the Inferior Pulmonary Ligament
Description: Patients will be categorized into two groups: the division group ,who will receive the division of the inferior pulmonary ligament, and the preservation group, who will not.For the dissection group, we will dissect the inferior pulmonary ligament during the surgery.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Preservation of the Inferior Pulmonary Ligament
Description: Patients will be categorized into two groups: the division group ,who will receive the division of the inferior pulmonary ligament, and the preservation group, who will not.For the preservation group, we will preserve the inferior pulmonay ligament during the surgery.
Study: NCT02439580

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Annona muricata extract
Description: ethanol-soluble fraction of water extract

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: maltose
Study: NCT01699139

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: positional device
Description: Avoidance of supine positioning was achieved by use of the commercially available ZZoma Positional Device, which is the FDA cleared class II positional medical device. The device is 12 x 5.5 x 4 inches in size and made of lightweight semi-rigid synthetic foam. It is contained in the nylon material with an associated Velcro belt. Zzoma is a positioner worn around the upper torso to restrict patient movement from side to supine.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: lumbar corset
Description: A lumbar (abdominal) binder is made of an elastic fabric with Velcro closure. Subjects wore the prefabricated lumbar corset during sleep and were positioned ad lib.
Study: NCT00491179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2a and ribavirin
Description: Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2a and ribavirin
Description: Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 24 weeks
Study: NCT01621685

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: biological/vaccine
Description: Inhalation studies will immediately be terminated after a significant adverse response to a particular capsaicin dose and no further testing will occur.
Study: NCT04684420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucophage® XR RM Test
Description: Participants received a single oral dose of 500 mg of test Glucophage® XR RM tablet under fasting or fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucophage® XR RM Test
Description: Participants received a single oral dose of 500 mg of test Glucophage® XR RM tablet under fasting or fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucophage® XR RM Test
Description: Participants received a single oral dose of 500 mg of test Glucophage® XR RM tablet under fasting or fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucophage® XR RM Test
Description: Participants received a single oral dose of 500 mg of test Glucophage® XR RM tablet under fasting or fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucophage® XR Reference
Description: Participants received a single oral dose of 500 mg of reference Glucophage® XR tablet under fasting or fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucophage® XR Reference
Description: Participants received a single oral dose of 500 mg of reference Glucophage® XR tablet under fasting or fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucophage® XR Reference
Description: Participants received a single oral dose of 500 mg of reference Glucophage® XR tablet under fasting or fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucophage® XR Reference
Description: Participants received a single oral dose of 500 mg of reference Glucophage® XR tablet under fasting or fed conditions.
Study: NCT02413437

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CEUS guided biopsy
Description: Biopsy was operated under contrast-enhanced ultrasound-guided.

Intervention type: OTHER
Group type: OTHER
Intervention: US guided biopsy
Description: Biopsy was operated under conventional ultrasound-guided.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound

Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrasound
Study: NCT01345500

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Higher Carbohydrate, Lower Fat Diet
Description: Study participants will receive prepackaged prepared foods as needed to achieve a meal plan, free-of-charge for a 12-month period. The lower fat, higher carbohydrate diet provides 60% energy from carbohydrate, 20% energy from fat, and 20% energy from protein. The diet falls within the range of current dietary recommendations.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower carbohydrate, Higher fat diet
Description: Study participants will receive prepackaged prepared foods as needed to achieve a meal plan, free-of-charge for a 12-month period. The lower carbohydrate, higher fat diet provides 45% energy from carbohydrate, 35% energy from fat, and 20% energy from protein. The diet falls within the range of current dietary recommendations.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Individualized Counseling
Description: Participants assigned to the usual care group will be provided consultation with a research staff dietetics professional, who will provide publicly available print material that describes dietary and physical activity guidelines to promote weight loss and maintenance, at baseline (after randomization) and again at 6 months.
Study: NCT03728387

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Pilates Exercise
Description: All evaluations of the individuals included in the study will be done by the physiotherapist.. For the second evaluation the same individuals will be visited by the same physiotherapist at least 7 days after the first evaluation and only the FAB-T scale will be applied. 34 volunteer individuals who will be randomly choosen among 84 individuals will be given a 6-week exercise training program. According to this 6 week program, individuals will be admitted to the exercise training program for 45-60 minutes with a physiotherapist for 3 days in a week. The exercise program will consist of a warm-up, a strength training and a cool-down section. Various exercise methods (clinical pilates exercises) and tools will be utilized to improve balance and mobility. Third assessment of FAB-T will be applied only to individuals participating in the 6-week exercise training program.
Study: NCT02084446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus: initial dose of 1 mg twice a day starting at Day 1. Dose will be adjusted to keep everolimus trough levels between 3 and 8 ng/mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Very Low Tacrolimus
Description: Tacrolimus: initial dose of 0.05 mg/kg twice a day starting at Day 1. Dose will be adjusted to keep tacrolimus trough levels between 4 and 7 ng/mL during the first 3 months and 2 and 4 ng/mL thereafter.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low Tacrolimus
Description: Tacrolimus: initial dose of 0.05 mg/kg twice a day starting at Day 1. Dose will be adjusted to keep tacrolimus trough levels between 4 and 7 ng/mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroids
Description: Corticoids: endovenous Methylprednisolone will be administered 30-60 minutes before the first 3 doses of r-ATG: 250 mg (D0) and 125 mg (D2 and D4); Prednisone, 10 mg per oral, will be administered before the last dose of r-ATG (D6). Maintenance with Prednisone at post-transplant period will be performed in accordance with center local practice, i.e., only in patients with chronic previous use of corticosteroids, as well as in patients with autoimmune disease (systemic lupus erythematous, rheumatoid arthritis, etc).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroids
Description: Corticoids: endovenous Methylprednisolone will be administered 30-60 minutes before the first 3 doses of r-ATG: 250 mg (D0) and 125 mg (D2 and D4); Prednisone, 10 mg per oral, will be administered before the last dose of r-ATG (D6). Maintenance with Prednisone at post-transplant period will be performed in accordance with center local practice, i.e., only in patients with chronic previous use of corticosteroids, as well as in patients with autoimmune disease (systemic lupus erythematous, rheumatoid arthritis, etc).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: All patients will receive induction with rabbit Thymoglobulin (r-ATG) in four doses of 1.5 mg/kg (maximum total dose of 6 mg/kg), administered according to center local practice (before graft revascularization and at days 2, 4, and 6 post-transplant).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thymoglobulin
Description: All patients will receive induction with rabbit Thymoglobulin (r-ATG) in four doses of 1.5 mg/kg (maximum total dose of 6 mg/kg), administered according to center local practice (before graft revascularization and at days 2, 4, and 6 post-transplant).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Mycophenolate
Description: Sodium Mycophenolate: initial dose of 720 mg twice a day starting at Day 1.
Study: NCT03889041

Intervention type: OTHER
Intervention: Quality of life assessment
Description: The Turkish Feeding/Swallowing Impact Survey will be completed by the caregivers
Study: NCT02765282

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Algorithm based programming using Kinesia-based assessment
Description: DBS-Expert includes a tablet-based software application (app) for guiding DBS programming and a Kinesia motion sensor unit for automated motor assessment. Algorithms search the programming parameter space to resolve an optimal set of programming parameters.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Algorithm based programming using Kinesia-based assessment
Description: DBS-Expert includes a tablet-based software application (app) for guiding DBS programming and a Kinesia motion sensor unit for automated motor assessment. Algorithms search the programming parameter space to resolve an optimal set of programming parameters.
Study: NCT02538302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minirin
Description: Minirin 5 to 10 mg daily for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxybutynin
Description: Oxybutynin 5 to 10 mg daily for 6 months
Study: NCT00002550

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT03765645

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperacillin + Tazobactam
Description: Antibiotic used will be Piperacillin + Tazobactam Dose: 4.5 g, thrice a day at regular intervals Route: Intra-venous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperacillin + Tazobactam
Description: Antibiotic used will be Piperacillin + Tazobactam Dose: 4.5 g, thrice a day at regular intervals Route: Intra-venous
Study: NCT02664116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac postassium powder for oral solution and placebo injection
Description: Diclofenac postassium powder for oral solution 50 mg in 1 ounce water orally, single dose and placebo normal saline 2ml intramuscular injection, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac intramuscular injection and placebo oral solution
Description: ketorolac 60 mg in 2 ml intramuscular injection, single dose and placebo oral solution, 1 ounce, single dose
Study: NCT03426176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxytocin nasal spray
Description: intranasal administration of oxytocin (24 IU)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxytocin nasal spray
Description: intranasal administration of oxytocin (24 IU)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal placebo treatment (placebo-control for oxytocin)
Description: intranasal administration of placebo nasal spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intranasal placebo treatment (placebo-control for oxytocin)
Description: intranasal administration of placebo nasal spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATD treatment
Description: oral administration of ATD (75.2g) (Acute Tryptophan Depletion)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATD treatment
Description: oral administration of ATD (75.2g) (Acute Tryptophan Depletion)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral placebo treatment (placebo-control for ATD)
Description: oral administration of a tryptophan-balanced mixture (78.2g)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oral placebo treatment (placebo-control for ATD)
Description: oral administration of a tryptophan-balanced mixture (78.2g)
Study: NCT02393911

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low Oxalate Diet
Description: Low oxalate diet is a diet where products with oxalate will be eliminated, such as: tomatoes, berries, coffee, nuts

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low Oxalate Diet
Description: Low oxalate diet is a diet where products with oxalate will be eliminated, such as: tomatoes, berries, coffee, nuts

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low Oxalate Diet
Description: Low oxalate diet is a diet where products with oxalate will be eliminated, such as: tomatoes, berries, coffee, nuts
Study: NCT01362582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SMOF Kabiven
Description: SMOFKabiven® will be given over night with a content of 1100 kcal in 986 ml.
Study: NCT03783949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganetespib
Description: Ganetespib dose during chemotherapy will be 150mg/m² (q3w) Ganetespib dose during maintenance treatment will be 100mg/m² (q1w)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganetespib
Description: Ganetespib dose during chemotherapy will be 150mg/m² (q3w) Ganetespib dose during maintenance treatment will be 100mg/m² (q1w)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib starting dose during maintenance treatment will be 200mg or 300mg depending on subject's body weight and subject neutrophil count (QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib starting dose during maintenance treatment will be 200mg or 300mg depending on subject's body weight and subject neutrophil count (QD)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niraparib
Description: Niraparib starting dose during maintenance treatment will be 200mg or 300mg depending on subject's body weight and subject neutrophil count (QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: In combination with Gemcitabine: Carboplatin dose will be AUC4 (q3w) In combination with Paclitaxel: Carboplatin dose will be AUC5 (q3w)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: In combination with Gemcitabine: Carboplatin dose will be AUC4 (q3w) In combination with Paclitaxel: Carboplatin dose will be AUC5 (q3w)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: In combination with Gemcitabine: Carboplatin dose will be AUC4 (q3w) In combination with Paclitaxel: Carboplatin dose will be AUC5 (q3w)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel dose will be 175mg/m² (q3w)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine dose will be 1000mg/m² (q3w, d1 \& d8)
Study: NCT02751528

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-021
Description: ETBX-021 is a HER2-targeting vaccine comprising an Ad5 vector and a modified HER2 gene insert.
Study: NCT02821013

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent PD-1 inhibitor therapy
Study: NCT03758755

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction Therapy
Description: A wide pressure cuff will be applied to the upper thigh prior to starting strengthening exercises. The cuff is inflated to 80% of resting systolic blood pressure. The cuff remains inflated for the entirety of the exercise (4 sets of a specific movement). Once the exercises are completed, it is deflated for a minimum of one minute before the next type of exercises are started.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACL Reconstruction rehabilitation
Description: post-operative rehabilitation according to current standards of care
Study: NCT02821013

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuous PD-1 inhibitor therapy
Study: NCT04783571

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Auditory stimulation will not be delivered during the nap

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Auditory stimulation will not be delivered during the nap

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auditory Stimulation
Description: Auditory stimulation will be delivered during the nap

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auditory Stimulation
Description: Auditory stimulation will be delivered during the nap
Study: NCT03546361

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Dendritic Cell-Adenovirus CCL21 Vaccine
Description: Given via CT-guided or bronchoscopic IT injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT02022605

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hands-on EMS training
Description: A trainer (SAH) gave a series of demonstrations of the proper techniques of ERCP step by step on the EMS. The demonstration included selective cannulation, sphincterotomy, guidewire exchange, balloon dilation, stone extraction and stent insertion. Then trainees practiced each technique with hands-on coaching from the trainer on the EMS. Each trainee could repeate the practice with the trainer giving only verbal correction of any errors for about 30min.
Study: NCT03817983

Intervention type: DIAGNOSTIC_TEST
Intervention: MRE review for evidence of axSpA in SIJs
Description: Screening for evidence of axSpA on the MRE scan of patients with Crohn's disease

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical assessment and dedicated MRI of the spine and pelvis
Description: Clinical assessment and dedicated MRI of the spine and pelvis to assess for evidence of axSpA

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical assessment and dedicated MRI of the spine and pelvis
Description: Clinical assessment and dedicated MRI of the spine and pelvis to assess for evidence of axSpA
Study: NCT02022605

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard training
Description: The standard cannulation technique was used with a sphincterotome preloaded with a guidewire, positioned in the ampullary orifice, and targeting the presumed entry of CBD or PD. During the whole procedure of cannulation by trainees, the senior endoscopist would actively communicate with trainees through verbal and/or hands-on assistance to help them to make the performance more correctly. If the trainees failed to enter the targeted duct within 10min, the senior endoscopist would take over the duodenoscope and continue the following procedure of cannulation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard training
Description: The standard cannulation technique was used with a sphincterotome preloaded with a guidewire, positioned in the ampullary orifice, and targeting the presumed entry of CBD or PD. During the whole procedure of cannulation by trainees, the senior endoscopist would actively communicate with trainees through verbal and/or hands-on assistance to help them to make the performance more correctly. If the trainees failed to enter the targeted duct within 10min, the senior endoscopist would take over the duodenoscope and continue the following procedure of cannulation.
Study: NCT02257047

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Tea

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RYR
Description: red yeast rice